Use of Ultra-Rapid Insulin Plus MiniMed 780G Raises Time in Range

Why It Matters

The findings demonstrate that ultra‑rapid insulin can safely enhance glycemic control in automated delivery systems, offering patients greater mealtime flexibility and reducing the risk of hyperglycemia without increasing hypoglycemia. This could accelerate adoption of faster insulins in closed‑loop therapy, reshaping diabetes management standards.

Key Takeaways

• Ultra‑rapid insulin lispro‑aabc with MiniMed 780G raised pediatric TIR to 68.6%.
• Adult TIR reached 77.6% using the same ultra‑rapid insulin system.
• No DKA or severe hypoglycemia reported during the 3‑month trial.
• Optimal settings (100 mg/dL target, 2‑hour active insulin) improved outcomes.
• >90% hybrid closed‑loop usage achieved across children and adults.

Pulse Analysis

Hybrid closed‑loop (HCL) systems have become the cornerstone of modern type 1 diabetes care, automating basal insulin delivery while leaving mealtime boluses to the user. The speed of the bolus insulin, however, remains a limiting factor because traditional rapid‑acting analogues require a 15‑ to 20‑minute pre‑meal window to align with glucose excursions. Eli Lilly’s ultra‑rapid insulin lispro‑aabc, marketed as Lyumjev, shortens that pharmacokinetic lag, promising tighter post‑prandial control. Pairing this faster insulin with Medtronic’s MiniMed 780G, which already delivers automated basal adjustments, creates a synergistic platform that could redefine “real‑time” glucose management.

The recent single‑arm study involving 110 adults and 101 youths confirmed the theoretical advantage. Pediatric participants lifted their time‑in‑range (TIR) from 51.2% to 68.6%, while adults moved from 67% to 77.6%, surpassing the thresholds set by the earlier MiniMed 670G pivotal trial. Importantly, the trial recorded zero cases of diabetic ketoacidosis or severe hypoglycemia, underscoring the safety of faster insulin kinetics within an algorithm‑driven loop. Over 90% of the cohort remained in hybrid closed‑loop mode, and the recommended 100 mg/dL target with a 2‑hour active insulin time proved pivotal for achieving adult‑level outcomes in children.

From a commercial perspective, these results could accelerate the rollout of ultra‑rapid insulins across HCL platforms, prompting device manufacturers to fine‑tune algorithms for faster pharmacodynamics. Payers may view the improved TIR and reduced hypoglycemia risk as cost‑saving, given the long‑term complications associated with poor glycemic control. Future head‑to‑head trials against standard rapid‑acting analogues will be essential to quantify incremental benefits, but the current data already signal a shift toward more flexible, patient‑centric dosing regimens. As adoption grows, both insulin producers and pump makers stand to capture new market share in the expanding diabetes technology ecosystem.